High PSALow volume diseaseRarely, patients with prostate cancer (PC) present with Prostate-Specific Antigen (PSA) scores >20ng/mL but otherwise very low-risk disease. Oncologists debate whether malignancies in these patients behave more comparably to low-risk or high-risk disease. Our objective ...
Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral ... Purpose;Prostate cancer (PCa) prevention remains an appealing strategy for the reduction of overtreatment and secondary adverse effects. We evalu...
Although the widespread use of prostate-specific antigen (PSA) testing has led to an increase in the number of cancers detected, controversies about the benefits of screening persist. No conclusive evidence has yet emerged that PSA screening reduces the mortality associated with prostate cancer. Thus...
1 In 2012, the US Preventive Services Task Force recommended against routine prostate-specific antigen (PSA) screening owing to risk of overdiagnosis of clinically insignificant prostate cancer. Consequently, there has been a decrease in indolent, localized disease, but a concordant increase of ...
PSMA expression and CD8+ T-cell infiltration in prostate tissue samples were compared with Wilcoxon rank-sum test [46]. When patients were dichotomised (high/high versus remaining), comparisons to clinical parameters (BCR, surgical margin status, pre-surgery PSA, CAPRA-S risk Score, T-stage ...
PSA velocity, and DRE and TRUS findings at initial biopsy were independent predictors of malignant disease on repeat biopsy The only independent histologic predictor of a cancer diagnosis was the number of cores with high-grade PIN Only independent variable predictive of positive biopsy was prostate ...
A 1:4 ratio propensity score matching (PSM) was performed to achieve baseline equivalence in age, body mass index (BMI), comorbidities, clinical stage, prostate specific antigen (PSA), prostate volume, biopsy grade, and number of positive cores. Functional outcomes based on International Prostate...
aMonitoring with PSA after treatment for prostate cancer is a mainstay of clinical practice, although the clinical utility of PSA is variable and depends on the disease stage of the indi-vidual patient. As has recently been observed, the lack of high quality information and paucity of clinical...
The median PSA at baseline was 1.77 ng/mL. The PSA doubling time was less than 3 months for 25.8% of patients and between 3 and 9 months for 74.2% of patients. The median time between radical prostatectomy and baseline was 4.4 years. Overall, 84.7% of patients had prior radiation and ...
HGPIN alone does not result in abnormal digital rectal examination nor elevated serum PSA. It may appear as a hypoechoic lesion on sonography, indistinguishable from pros- tate carcinoma. The clinical importance of a HGPIN diagnosis in prostate biopsies is the risk of cancer detection in subsequent...